LifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma that will focus on developing cancer drugs. The combined company will be ...
Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital, amongst others. The cash will be used for further clinical development of Enliven’s two lead candidates, BCR-ABL inhibitor ELVN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
